Cargando…

Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer

BACKGROUND: Zimberelimab (GLS-010) is a novel fully human monoclonal immunoglobulin G4 (IgG4) against the programmed cell death-1 (PD-1) receptor. AIM: To evaluate the affinity, competitive blocking capability, T cell activation effect, cytotoxic effector functions by Fc, preliminary anti-tumor acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lou, Beilei, Wei, Hua, Yang, Fang, Wang, Shicong, Yang, Baotian, Zheng, Yong, Zhu, Jiman, Yan, Shaoyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479189/ https://www.ncbi.nlm.nih.gov/pubmed/34604074 http://dx.doi.org/10.3389/fonc.2021.736955

Ejemplares similares

Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer
por: Chen, Yeshan, et al.
Publicado: (2022)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights
por: Zhang, Danfeng, et al.
Publicado: (2023)

METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression
por: Chen, Xiaoting, et al.
Publicado: (2021)

SNAP25 Inhibits Glioma Progression by Regulating Synapse Plasticity via GLS-Mediated Glutaminolysis
por: Huang, Qiongzhen, et al.
Publicado: (2021)

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
por: Zeligs, Kristen P., et al.
Publicado: (2020)

Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer
por: Saha, Subbroto Kumar, et al.
Publicado: (2019)

Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells
por: Szeliga, Monika, et al.
Publicado: (2013)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Prediction of cardiac events using fully automated GLS and BNP titers in patients with known or suspected heart failure
por: Otani, Kyoko, et al.
Publicado: (2020)

Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
por: Peng, Xiao-Dong, et al.
Publicado: (2023)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings
por: Germovsek, Eva, et al.
Publicado: (2021)

Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
por: Fan, Shanmin, et al.
Publicado: (2023)

Concurrent Ocular Myopathy and Myasthenia Gravis After Zimberelimab Therapy in a Patient With Non-Small-Cell Lung Cancer
por: Kim, Haelim, et al.
Publicado: (2022)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

GLS2 shapes ferroptosis in hepatocellular carcinoma
por: Suzuki, Sawako, et al.
Publicado: (2023)

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
por: Cai, Wen-Qi, et al.
Publicado: (2020)

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
por: Schmidt, Gilda, et al.
Publicado: (2022)

Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report
por: Li, Jie, et al.
Publicado: (2023)

Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis
por: Chattopadhyaya, Sikta, et al.
Publicado: (2022)

Anti–PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment
por: Hua, Yonghong, et al.
Publicado: (2022)

P010 Abstract Withdrawn
Publicado: (2021)

A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK
por: Halford, Michael M., et al.
Publicado: (2013)

Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
por: Mata-Molanes, Juan J., et al.
Publicado: (2022)

Acute low back pain as infusion-related reaction to monoclonal antibodies
por: Majenka, Pawel, et al.
Publicado: (2023)

Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use
por: Stevens, Misty W, et al.
Publicado: (2014)

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
por: Pierpont, Timothy M., et al.
Publicado: (2018)

Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer
por: Zhang, Junfeng, et al.
Publicado: (2019)

Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model
por: Brady, Jamie L, et al.
Publicado: (2014)

“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients
por: Zhang, Guoqing, et al.
Publicado: (2022)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

A fully caninised anti-NGF monoclonal antibody for pain relief in dogs
por: Gearing, David P, et al.
Publicado: (2013)

Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B
por: Matsumura, Takuhiro, et al.
Publicado: (2020)

Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase
por: Kaewchim, Kanasap, et al.
Publicado: (2021)

Single Pd Atoms on θ-Al(2)O(3) (010) Surface do not Catalyze NO Oxidation
por: Narula, Chaitanya K., et al.
Publicado: (2017)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlf73hfk8r9c9mkeevbc7qoij7